Tag: KDC-MN-238

  • Lurasidone

    Atypical antipsychotic with 5-HT7 antagonism

    A benzisothiazole atypical antipsychotic with prominent 5-HT7 receptor antagonism contributing to procognitive and antidepressant effects.

    Abstract

    Lurasidone ((3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]-cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione; CAS 367514-87-2; molecular formula C28H36N4O2S; molecular weight 492.68) is a benzisothiazole atypical antipsychotic developed at Sumitomo Dainippon and approved by the FDA in 2010 under the trade name Latuda. The receptor profile features full D2 antagonism (Ki approximately 1 nM), potent 5-HT2A antagonism (Ki approximately 0.5 nM), 5-HT1A partial agonism (Ki approximately 6.4 nM), and prominent 5-HT7 antagonism (Ki approximately 0.5 nM, the most potent in clinical use). The 5-HT7 antagonism is associated with procognitive effects and improvement in bipolar depression. H1 and muscarinic activity is minimal, producing low sedation and metabolic burden compared to olanzapine and quetiapine; the principal limitation is dose-related akathisia. Plasma half-life is 18 hours; absorption requires food (approximately 350 kcal). Metabolism is via CYP3A4. Approved for schizophrenia (acute and maintenance), bipolar I depression (monotherapy or with lithium/valproate). Used as the reference 5-HT7-prominent antipsychotic.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.